AlgoTherapeutix appoints Agathe Nadolny Chief Project Management Officer

Paris, Dec 16th 2021 – AlgoTherapeutix (AlgoTx) is a European Biotech developing ATX01, a non-opioid topical treatment for Peripheral Neuropathic Pain.

Stéphane Thiroloix, CEO, comments : “Project Management is a crucially important and arduous function in an R&D company. We are delighted to welcome such a talented expert as Agathe to the team”.

.

Agathe Nadolny, MSc, PMP®, brings to AlgoTx over 20 years of experience in healthcare product management across R&D, manufacturing and strategic planning. She held positions of increasing responsibility at Bio-Rad from 2001 to 2017, eventually joining the Executive Committee as Project Management Office Manager. Prior to joining AlgoTx, Agathe was the New Product Launch Program Manager at French Pharma Mayoly Spindler.

.

Agathe joins AlgoTx just as the pivotal Phase II trial in is preparation. Her role involves the planning and coordination of all actions, parties and deliverables, not only in R&D but also on the general strategic roadmap of AlgoTx.

.

About AlgoTherapeutix : AlgoTherapeutix is a French biotech founded in 2018 to develop innovative solutions for complex pain. Its lead program, ATX01, is entering Phase II in painful peripheral neuropathy.

.